Recombinant Human Interferon Alpha 2b In PFS

DESCRIPTION:

colorless transparent liquid, without visible undissolved particles.

INDICATIONS:

Interferon is indicated to treat the following diseases: Acute or chronic viral hepatitis (Type B, Type C, etc. ), infantile viral pneumonia, infantile viral myocarditis, herpes zoster, condylomata acuminata,viral rheum, hairy cell leukemia, chronic myeloid leukemia, Kaposis sarcoma,multiple myeloma, T-cells lymphoma, malignant melanoma, laryngeal papillomatosis, basal cell carcinoma,surface bladder carcinoma, kidney carcinoma.

ADMINISTRATION AND DOSAGE:

Kawin Interferon is administered intramuscular, subcutaneous or intratumoral injection.

1. Chronic viral hepatitis B: 3-6MIU once daily, administered subcutaneously or intramuscularly, continuously for 4 weeks. Then three times a week for more than 16 weeks. The physician may adjust dosage according to patients response and tolerance to medication.

2. Acute and Chronic viral hepatitis C: 3-6MIU once daily, administered subcutaneously or intramuscularly, continuously for 4 weeks. Then three times a week for more than 16 weeks. The physician may adjust dosage according to patients response and tolerance to medication.

3. Herpes zoster: 1MIU administered intramuscularly once daily, continuously for 6 days. And taking orally acyclologuanosine at the same time. The physician may adjust dosage according to patients response and tolerance to medication.

4. Condylomata acuminata: 1-3MIU administered intramuscularly, continuously for 4 weeks. Another method is 1MIU injected in the base of wart, simultaneously treating with laser or electrotherapeutics.

5. Hairy cell leukemia: 2-8MIU/m² administered once daily, continuously for not less than 3 months. The physician may adjust dosage according to patients response and tolerance to medication. The response is achieved usually after 1-2 months of treatment. Long-term palliation may be achieved by intermittence treatment of KAFERON.

6. Chronic myeloid leukemia: 3-5MIU/m² once daily administered intramuscularly, also can be administered simultaneously with chemotherapy medicines such as hydroxycarbamide or Ara-C. All patients with complete hematological responses should continue injection every other day. The cytogenetic changes may be achieved in 9-10 months. The physician may adjust dosage according to patients response and tolerance to medication.

7. Multiple myeloma: 3-5MIU/m² administered intramuscularly three times a week, simultaneously with chemotherapy such as VMCP. The physician may adjust dosage or combine with other drugs according to patients response and tolerance to medication.

8. Malignant melanoma: 6MIU administered intramuscularly three times a week, simultaneously with chemotherapy.

9. Lymphoma: 3-5MIU/m² administered intramuscularly three times a week, simultaneously with chemotherapy such as CHVP. The physician may gradually increase dosage according to patients response and tolerance to medication until reach the maximum dosage for 8-12 weeks. The treatment should be maintained for 12 months unless disease progresses rapidly or server intolerance occurs. The physician may adjust dosage according to patients response and tolerance to medication.

10. Kidney carcinoma: 6MIU administered intramuscularly three times a week, simultaneously with chemotherapy.

11. AIDS related Kaposis sarcoma: 50MIU/m² infused daily, continuously for 5 days. The infusion time should not be less than 30 minutes. Next course is started after at least a 9-day-break.

12. Basal cell carcinoma: 5MIU injected intratumoraly three times a week for three weeks.

13. Ovary carcinoma: 5-8MIU administered intramuscularly three times a week, simultaneously with chemotherapy.

See detailed information on Kawin's company homepage.